TNF and Crohn disease: Common complications of Crohn's disease include strictures, fistulas, and abscesses, and surgery is frequently required to address these complications.1, 2 Over the last few decades, biological agents have emerged as a pivotal treatment option in moderate to severe inflammatory bowel disease.3 The fully humanized monoclonal antitumor necrosis factor (TNF)‐α agent adalimumab (ADL), which is administered subcutaneously using a standardized treatment regimen, is well documented to induce and maintain disease remission in moderate to severe Crohn's disease.4, 5, 6